Replies to post #204594 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

When was the last time Anavex ran a phase 1?

2011?

Your argument is a FAIL.

Search
Hoboken, NJ — May 23, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the first group of healthy human volunteers in the initial dose step, the Safety Review Committee for ANAVEX 2-73 unanimously approved skipping the 5 mg dose and moving directly to the 10 mg dose step. The next group of eight healthy volunteers was dosed late last week. The clinical trial protocol allowed for the next dose to be studied as either 5 mg or 10 mg, if the safety review warranted the higher dose.

https://www.anavex.com/anavex-2-73-advances-phase-i-clinical-trial-for-alzheimers-disease/